Development of a FOXM1-DBD Binding Assay for High-Throughput Screening Using TR-FRET Assay

Biol Pharm Bull. 2021;44(10):1484-1491. doi: 10.1248/bpb.b21-00322.

Abstract

Electrophoretic mobility shift assay (EMSA) technology has been widely employed for the analysis of transcription factors such as Forkhead box protein M1 (FOXM1). However, the application of high-throughput screening (HTS) in performing, such analyses are limited as it uses time consuming electrophoresis procedure and radioisotopes. In this study, we developed a FOXM1-DNA binding domain (DBD) binding assay based on time-resolved fluorescence energy transfer (TR-FRET) that enables HTS for the inhibitors of FOXM1-DNA interaction. This assay was robust, highly reproducible and could be easily miniaturized into 384-well plate format. The signal-to-background (S/B) ratio and Z' factor were calculated as 7.46 and 0.74, respectively, via a series of optimization of the assay conditions. A pilot library screening of 1019 natural compounds was performed using the FOXM1-DBD binding assay. Five hit compounds, namely, AC1LXM, BRN5, gangaleoidin, leoidin, and roemerine were identified as the inhibitors of FOXM1. In a cell viability assay, it was demonstrated that cell proliferation of FOXM1 overexpressed cell lines was suppressed in cell lines such as MDA-MB-231 and MCF-7 by five hit compounds. These results indicate that developed FOXM1-DBD binding assay can be applied to highly efficiency HTS of compound libraries.

Keywords: Forkhead box protein M1; high-throughput screening; protein–DNA interaction.

MeSH terms

  • DNA / metabolism
  • Drug Discovery / methods
  • Fluorescence Resonance Energy Transfer
  • Forkhead Box Protein M1 / antagonists & inhibitors
  • Forkhead Box Protein M1 / metabolism*
  • High-Throughput Screening Assays / methods*
  • Humans
  • MCF-7 Cells
  • Protein Binding / drug effects
  • Protein Interaction Domains and Motifs

Substances

  • FOXM1 protein, human
  • Forkhead Box Protein M1
  • DNA